Abstracts tagged "SLE"

Abstract Number: 1611 • 2014 ACR/ARHP Annual Meeting
Modular Transcriptional Neutrophil Signature As Predictive of Nephritis and of Its Severity in SLE Patients
Noémie Jourde-Chiche Sr.¹, Stéphane Burtey², Nathalie Bardin³, Elizabeth Whalen⁴, Bertrand Gondouin⁵, Scott Presnell⁶, Bertrand Dussol⁷, Gilles Kaplanski⁸, Jean-Robert Harle⁹, Yvon Berland², Virginia Pascual¹⁰, Damien Chaussabel⁴ and Laurent Chiche¹¹, ¹Nephrology, Aix-Marseille Université - APHM, Marseille, France, ²Nephrology, APHM, Marseille, France, ³Hopital de la Conception, Marseille, France, ⁴BRI, seattle, WA, ⁵Department of Nephrology, APHM, Marseille, France, ⁶bri, seattle, WA, ⁷AP Marseille, Marseille, France, ⁸INSERM U608, Marseille, France, ⁹Internal Medicine, APHM, Marseille, France, ¹⁰Baylor University, Dallas, TX, ¹¹147 Boulevard Baille, CHU Marseille, Marseille, France
Background/Purpose: Lupus nephritis (LN) is a serious complication of SLE. Reliable biomarkers to assess and/or predict renal involvement in SLE patients are needed. The aim…
Abstract Number: 681 • 2014 ACR/ARHP Annual Meeting
Hydroxychloroquine Use Is Associated Independently with Improved Quality of Life in Systemic Lupus Erythematosus
Meenakshi Jolly¹, Winston Sequeira², Sarfraz Hasni³, Zulfiqar Ali⁴, Sergio Toloza⁵, Ana M. Bertoli⁶, Ivana Blazevic⁷, Luis M. Vila⁸, Ioana Moldovan⁹, Karina D Torralba¹⁰, Berna Goker¹¹, Josiane Bourré-Tessier¹², S. Navarra¹³, Daniel Wallace¹⁴, Michael H. Weisman¹⁵, Ann E. Clarke¹⁶ and Chi Chiu Mok¹⁷, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Medicine/Rheumatology, Rush University, Chicago, IL, ³NIH, BETHESDA, MD, ⁴NIH, Bethesda, MD, ⁵Hospital San Juan Bautista, San Fernando del Valle de Catamarca, Argentina, ⁶Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, ⁷University of Buenos Aires, Buenos Aries, Argentina, ⁸Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁹Rheumatology, Beaver Medical Group, Redlands, CA, ¹⁰University of Southern California, LA, CA, ¹¹Department of Internal Medicine- Rheumatology, Gazi University School of Medicine, Ankara, Turkey, ¹²Department of Medicine, Division of Rheumatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ¹³University of Santo Tomas Hospital, Manila, Philippines, ¹⁴UCLA, LA, CA, ¹⁵Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁶Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁷Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: Hydroxychloroquine (HCQ) has been shown to be beneficial to patients with Systemic Lupus Erythematosus (SLE), however, its effects on the quality of life (QOL)…
Abstract Number: 2797 • 2013 ACR/ARHP Annual Meeting
B-Lymphocyte Stimulator and A Proliferation Inducing Ligand In Lupus Nephritis: Low Serum Levels Of BLyS Predict Treatment Response
Ioannis Parodis¹, Agneta Zickert¹, Elisabet Svenungsson², Vivianne Malmström² and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: B-lymphocytes have a pivotal role in the pathogenesis of Systemic Lupus Erythematosus (SLE). B-Lymphocyte Stimulator (BLyS) has an important role in the activation, differentiation…
Abstract Number: 1630 • 2013 ACR/ARHP Annual Meeting
Association Of TREM-Like Transcript-1 With Systemic Lupus Erythematosus
Yerania Rodríguez-Navedo¹, Karina Vilá -Rivera¹, Mariely Nieves-Plaza², Martha Ricaurte³, A. Valance Washington³ and Luis M. Vilá¹, ¹Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²University of Pittsburgh, Pittsburgh, PA, ³University of Puerto Rico, Río Piedras Campus, San Juan, PR
Background/Purpose: Recent studies suggest that a platelet α-granule protein named TREM-like transcript-1 (TLT-1) is a key molecule in modulating the inflammatory response. TLT-1 has been…
Abstract Number: 1572 • 2013 ACR/ARHP Annual Meeting
High Type I Interferon In Systemic Lupus Erythematosus Plasma Predicts Future Renal Disease
Kyriakos A. Kirou¹, Mikhail Olferiev¹, Elzbieta E. Jacek¹, Mari Lliguicota¹, Margaret Robotham¹, Wei-Ti Huang², Elena Gkrouzman¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Biostatistics, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Type I interferon (IFN-I) is elevated in many patients with SLE and is associated with more severe disease. However, the relationship between elevated levels…
Abstract Number: 640 • 2013 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Patients With Atherosclerosis Are Characterised By a Distinct Invariant Natural Killer T Cell Phenotype and Altered CD1d-Mediated Lipid Antigen Presentation
Edward Smith¹, Sara Croca², Andrew Pitcher¹, D.A. Isenberg¹, Anisur Rahman³ and Elizabeth C. Jury⁴, ¹Centre for Rheumatology Research, University College London, London, United Kingdom, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ⁴Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: It is widely reported that systemic lupus erythematosus (SLE) patients have an increased risk of atherosclerosis compared to the general population, irrespective of traditional…
Abstract Number: 32 • 2013 ACR/ARHP Annual Meeting
Understanding The Stimulatory Pathways Responsible For Naïve B Cell Activation In Systemic Lupus Erythematosus
Emily Blalock¹, Chris Scharer², Scott Jenks¹, Jeremy Boss² and Ignacio Sanz³, ¹Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, ³Allergy, Immunology and Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a recurrent autoimmune disease characterized by multiple B cell abnormalities, including the activation of naïve B cells. However, gaps…
Abstract Number: 2737 • 2013 ACR/ARHP Annual Meeting
In Vivo MiR-146a Administration Ameliorates Murine Lupus Nephritis
Dong Liang¹, Shiyu Zhou², Zheng Liu³, Zhengyuan Shan¹, Philip Brohawn³, Yihong Yao³, Indu Raman⁴, Quan-Zhen Li⁴, John B. Harley^5,6 and Nan Shen^1,2,7, ¹Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁴Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁶US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁷Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: New Zealand black and white F1 (NZBW/F1) is a classic mouse model of systemic lupus erythematosus (SLE). Type I interferon (IFN) infusion accelerates lupus…
Abstract Number: 1631 • 2013 ACR/ARHP Annual Meeting
Transcription Activation-Like Effector Nuclease-Mediated Enhancer Knockout Influences TNFAIP3 Gene Expression and Mimics a Functional Phenotype Associated With Systemic Lupus Erythematosus
Shaofeng Wang¹, Feng Wen², Bo He³ and Patrick M. Gaffney⁴, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Emerging technologies for precise, targeted genome editing provide new opportunities for the functional elucidation of causal genetic variants and genomic elements without the confounding…
Abstract Number: 1581 • 2013 ACR/ARHP Annual Meeting
Lipid Lowering Medication Use Is Associated With Reduced Muscle Strength In Systemic Lupus Erythematosus
James S. Andrews¹ and Patricia P. Katz², ¹Rheumatology, University of California San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Premature atherosclerotic coronary artery disease is a major source of morbidity for women with systemic lupus erythematosus (SLE). Lipid lowering medications (LLM) are among…
Abstract Number: 604 • 2013 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Is Not Associated With Reduced Cardiovascular Or Lupus Damage Accumulation In a Cross-Sectional Lupus Cohort Study
Maureen A. McMahon¹, Maria Dall'era², Eliza Chakravarty³, Joseph E. Craft⁴, Gary S. Gilkeson⁵, Kenneth C. Kalunian⁶, R. John Looney⁷, Gerald McGwin Jr.⁸ and Meggan Mackay⁹, ¹Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Yale University School of Medicine, Internal Medicine, Section of Rheumatology, New Haven, CT, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶UCSD School of Medicine, La Jolla, CA, ⁷Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁸Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁹Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Mycophenolate mofetil (MMF) is frequently used for the treatment of lupus. The immune-modulating effects of MMF extend beyond effects on lymphocyte proliferation, and include…
Abstract Number: 34 • 2013 ACR/ARHP Annual Meeting
Dichotomous Responses Of Human Systemic Lupus Erythematosus B Cell Subsets To B Cell Receptor Stimulation
Franziska Matzkies¹, Anthony DeFranco², Andrew J. Gross³, Maria Dall'era⁴ and Michelle Hermiston⁵, ¹Medicine- Rheumatology, University of California, San Francisco, San Francisco, CA, ²Microbiology & Immunology, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵Pediatrics, Hematology/Oncology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Autoantibody production is a hallmark of Systemic Lupus Erythematosus (SLE), supporting a central role for B cells in disease pathogenesis. Prior studies have demonstrated…
Abstract Number: 2722 • 2013 ACR/ARHP Annual Meeting
In Vivo Administration Of MiR-146a Protects C57BL/6 Mice From Pristane-Induced Pulmonary Hemorrhage Via Suppressing Type I Interferon Response
Dong Liang¹, Shiyu Zhou², Zheng Liu³, Zhengyuan Shan¹, Philip Brohawn³, Yihong Yao³, John B. Harley^4,5 and Nan Shen^1,2,6, ¹Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁴Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁶Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: miR-146a as an endogenous regulator plays a critical role in resolving acute inflammation. The risk-associated genetic variant in miR-146a promoter was linked to reduced…
Abstract Number: 1636 • 2013 ACR/ARHP Annual Meeting
Pro-Inflammatory HDL and Subclinical Atherosclerosis Are Associated With Altered Expression Of Epigenetic and Oxidative Stress-Related Gene Transcripts In SLE
Brian Skaggs¹, Bevra H. Hahn², Jennifer M. Grossman³, Elaine Lourenco¹, Isao Matsuura⁴, Lori Sahakian⁵ and Maureen A. McMahon⁶, ¹Medicine/Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Division of Rheumatology, Department of Medicine,, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁶Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Premature atherosclerosis is widely recognized as a significant co-morbid condition of systemic lupus erythematosus (SLE), but exact mechanisms are unknown. Although traditional cardiovascular risk…
Abstract Number: 1061 • 2013 ACR/ARHP Annual Meeting
Clinical Phenotypes and Disease Burden Of Discoid Lupus Erythematosus In a Sample Of Systemic Lupus Erythematosus Patients In The Southeastern United States
Leslie Anne Cassidy¹, Gaobin Bao², Charmayne M. Dunlop-Thomas³, S. Sam Lim⁴ and Cristina Drenkard^5,6, ¹Department of Medicine, Division of Rheumatology, Emory University, Atlanta, GA, ²Medicine, Emory University, Atlanta, GA, ³Medicine Rheumatology, Emory University, Atlanta, GA, ⁴Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ⁵Department of Medicine, Emory University, Atlanta, GA, ⁶Epidemiology, Emory Rollins School of Public Health, Atlanta, GA
Background/Purpose: The rash of discoid lupus erythematosus (DLE) has been reported in 10-25% of patients with systemic lupus erythematosus (SLE). Prior reports suggest that DLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].